|
NxStage Extends Supply Agreement with B.
Braun Medical Inc. to Include Streamline(R) Technology
LAWRENCE, Mass., June 1 /PRNewswire-FirstCall/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of
innovative dialysis products, today announced that its
Medisystems in-center business has completed development of the
new Streamline blood tubing sets for use on the B. Braun
Dialog(R) and Dialog Plus hemodialysis systems in the U.S. In
connection with this development, NxStage and B. Braun have
agreed to extend their supply agreement under which NxStage will
supply B. Braun with the new Streamline sets and B. Braun will
provide sales, marketing, and clinical support to its U.S.
customers.
"The launch of Streamline for the B. Braun machines broadens our
relationship and extends the value of our product portfolio to
B. Braun's Renal Therapies Division giving patients and
providers greater access to NxStage's high quality, value-added
in-center offerings," said Jeffrey H. Burbank, President and
Chief Executive Officer of NxStage Medical. "Streamline's
ability to improve patient clearances and reduce cost is yet
another example of NxStage's ability to innovate and bring value
in the form of both clinical benefits and operational savings."
"We are pleased to broaden our relationship with NxStage by
offering the unique Streamline technology to our dialysis
customers," stated Samuel Amory, Vice President, B. Braun
Medical Renal Therapies Division. "We look forward to leveraging
Streamline's benefits with our state-of-the-art Dialog
hemodialysis system and growing our business with NxStage."
NxStage's latest generation blood tubing set is the Streamline.
Streamline features an efficient and airless design intended to
improve clinical and economic performance. Streamline is
designed to reduce dialysate flow, dialyzer size, treatment
time, minimize heparin and waste, and optimize dose delivery, as
measured in Kt/V. Streamline also includes NxStage's patented
LockSite(R) needleless access ports, which eliminate the need
for sharp needles or costlier guarded needles to be used with
the tubing set during dialysis.
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain
management products with an environmentally-friendly focus.
Guided by the company's "Sharing Expertise(R)" philosophy, B.
Braun addresses the critical issues of infection prevention,
medication safety and environmental responsibility by promoting
best practices that help clinicians reduce medication errors,
prevent healthcare-acquired infections (HAIs) and achieve
sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its
medical technology and support services, B. Braun employees
share their knowledge with colleagues and customers to improve
working processes in hospitals and medical practices and to
enhance the safety of patients and healthcare professionals. For
more information, call 800-227-2862, e-mail B. Braun at
inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device
company, headquartered in Lawrence, Massachusetts, USA, that
develops, manufactures and markets innovative products for the
treatment of ESRD and acute kidney failure. For more information
on NxStage and its products, please visit the company's website
at
http://www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors including, but not limited
to, changes relating to customer demand for NxStage's Streamline
blood tubing sets and other factors that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including the Quarterly Report on Form 10-Q for the quarter
ended March 31, 2009. NxStage is under no obligation to (and
expressly disclaims any such obligation to) update or alter its
forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
Kristen K. Sheppard, Esq.
VP, Investor Relations
978-332-5923
ksheppard @nxstage.com
Source
NxStage Medical, Inc.
|
